Intraventricular enzyme delivery for lysosomal storage diseases
US10080783B2 · kind B2 · utility
6Cited by
9References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 3, 2014 |
| Grant date | Sep 25, 2018 |
| Priority date | — |
| Expiry date | Dec 3, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease. The administration can be performed slowly to achieve maximum effect. Surprisingly, effects are seen on both sides of the blood-brain barrier, making this an ideal delivery means for lysosomal storage diseases which affect both brain and visceral organs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.